This review highlights that current clinical guidelines recommend lifestyle modifications and targeted pharmacotherapy, including high-dose omega-3 fatty acids, primarily to prevent acute pancreatitis in patients with severe hypertriglyceridemia.
Answers are grounded in this paper and cite their sources.
Supports guideline-directed lifestyle and TG-lowering therapy to prevent pancreatitis; leaves open optimal agents and thresholds for trials.
Cardiovascular (CV) disease remains the leading cause of preventable death in the US. Hyperlipidemia is a major modifiable risk factor for CV disease, and after numerous clinical trials have demonstrated that reductions in low-density lipoprotein (LDL) cholesterol with statin therapy can prevent major adverse CV events, statins have emerged as the drug of choice to lower LDL cholesterol and reduce CV risk. However, some statin-treated patients remain at high residual risk of CV events despite achieving low LDL cholesterol levels, especially if their triglyceride (TG) levels are elevated or their high-density lipoprotein (HDL) cholesterol levels low. Evidence from genetic and observational studies has linked elevated TG levels to an increased risk of CV events. Furthermore, very high TG levels are associated with acute pancreatitis. Consequently, several clinical practice guidelines provide recommendations for the management and treatment of high and very high TG levels. This review focuses on the clinical practice guidelines for the management of hypertriglyceridemia and the role of prescription omega-3 fatty acids in preventing pancreatitis and CV disease in individuals with high and very high TG levels.
No takes yet. Share an insight, caveat, or question.
Dean G. Karalis (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: